title: Evaluation of adjuvant therapy after surgery for primary carcinoma of the fallopian tube.
abstract: OBJECTIVE
  To evaluate the impact of postoperative therapy (chemotherapy vs. irradiation) on overall survival.
  
  
  METHODS
  A nationwide retrospective analysis.
  
  
  METHODS
  Hanusch-Krankenhaus, Department of Gynaecology,
  
  
  METHODS
  115 patients with histologically proved primary carcinoma of the Fallopian tube: 49 received six treatment cycles of a cis-platinum regimen (group I), 24 patients were treated by full irradiation using 50 Gray minimum (group II). The two groups had a similar distribution of stage I and II; in the more advanced stages chemotherapy was the predominant method of treatment.
  
  
  RESULTS
  The five-year survival rate was 53% for women receiving irradiation as against 27% for those given cis-platinum. If the analysis was restricted to those patients with comparable stage I and stage II lesions, the p-value (0.07) was of borderline significance. There was no advantage in adding abdominal to pelvic irradiation (P = 0.62).
  
  
  CONCLUSIONS
  Stage I and stage II carcinoma is probably better treated postoperatively by radiotherapy than chemotherapy. Chemotherapy may have more therapeutic potential in patients with more advanced lesions.
authors.affiliation: Department of Gynaecology, Hanusch-Krankenhaus, Vienna, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Klein
authors.forename: A
authors.initials: A
authors.lastname: Rosen
authors.forename: M
authors.initials: M
authors.lastname: Lahousen
authors.forename: A
authors.initials: A
authors.lastname: Graf
authors.forename: N
authors.initials: N
authors.lastname: Vavra
authors.forename: B
authors.initials: B
authors.lastname: Pakisch
authors.forename: J
authors.initials: J
authors.lastname: Poschauko
authors.forename: A
authors.initials: A
authors.lastname: Beck
authors.forename: H
authors.initials: H
authors.lastname: Kucera
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate
chemical_list: D002945:Cisplatin